Zimbabwe has declined a significant American healthcare agreement valued at 367 million US dollars (£272m) over five years due to the United States' demand for confidential information.
The decision came to light following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesman later stated that the United States was demanding access to genetic material for scientific study and profit while was not willing to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more talks to find a deal agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Background
This development follows a similar situation in Kenya, where a court blocked a similar deal with the US after legal challenges were filed about the safety of citizens' health data.
Since resuming office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and accountability.
Based on reports, Sixteen African countries have so far signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to share its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the final treatments would be available to our citizens should a future pandemic arise."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting structures previously set up via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This framework is intended to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent co-operation could be structured in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but urged that talks should continue given that a large portion of the country's Aids initiatives were funded by external financing.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," it added.
The halted deal highlights the complex tensions between accepting vital international aid and protecting a country's data in an ever more data-driven world.